Imaging Recommendations for Positron Emission Tomography (PET) in Oncology

Abstract

Cancer is one of the leading causes of morbidity and mortality. Imaging studies are central to the initial staging and follow-up management of cancers. In the past, oncologists have largely relied on anatomical imaging for staging, restaging, and therapy monitoring. The introduction of positron emission tomography-computed tomography (PET-CT) and its availability has transformed the practice of cancer imaging. PET-CT is an imaging technique that provides complementary information to imaging by CT or magnetic resonance imaging alone as it incorporates functional imaging to the anatomic information. It actually embeds tumor biology on the anatomical image. There are significant contributions of the CT component in adding value to the strength of PET-CT. PET-CT is useful for initial staging of cancers. It is particularly useful in detection of distant metastases, in assessing response to therapy and in detection of recurrence. Its utility in restaging and follow-up of cancers is now well established. Its role varies across different primary cancer sites. To cover the role of PET-CT in all cancer types is neither the intention nor feasible in a single article. In this article, an attempt will be made to highlight the generic concepts of PET-CT imaging and its role in primary staging and post-therapy follow-up across some common malignancies. Its pitfalls and limitations will also be discussed.

Keywords

imaging - oncology - PET-CT

Publication History

Article published online:
12 May 2023

• References

• 1 Kapoor V, McCook BM, Torok FS. An introduction to PET-CT imaging. Radiographics 2004; 24 (02) 523-543
• 2 Czernin J, Allen-Auerbach M, Nathanson D, Herrmann K. PET/CT in oncology: current status and perspectives. Curr Radiol Rep 2013; 1 (03) 177-190
• 3 National Oncologic PET Registry (NOPR). . Accessed December 11, 2022, at: https://clinicaltrials.gov/ct2/show/NCT00868582
• 4 Boellaard R, Delgado-Bolton R, Oyen WJ. et al; European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42 (02) 328-354
• 5 Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S. et al; Oncology Task Force of the Spanish Society of Nuclear Medicine and Molecular Imaging. 18F-FDG PET/CT in breast cancer: evidence-based recommendations in initial staging. Tumour Biol 2017; 39 (10) 1010428317728285
• 6 National Comprehensive Cancer Network (NCCN). . Accessed December 11, 2022, at: http://www.nccn.org/
• 7 Goel R, Moore W, Sumer B, Khan S, Sher D, Subramaniam RM. Clinical practice in PET/CT for the management of head and neck squamous cell cancer. AJR Am J Roentgenol 2017; 209 (02) 289-303
• 8 Sirohi B, Shrikhande SV, Perakath B. et al. Indian Council of Medical Research consensus document for the management of colorectal cancer. Indian J Med Paediatr Oncol 2014; 35 (03) 192-196
• 9 Van Cutsem E, Verheul HM, Flamen P. et al. Imaging in colorectal cancer: progress and challenges for the clinicians. Cancers (Basel) 2016; 8 (09) 81
• 10 Vikram R, Iyer RB. PET/CT imaging in the diagnosis, staging, and follow-up of colorectal cancer. Cancer Imaging 2008; 8 Spec No A (Spec Iss A): S46-S51
• 11 Shreve P, Faasse T. Role of positron emission tomography-computed tomography in pulmonary neoplasms. Radiol Clin North Am 2013; 51 (05) 767-779
• 12 Cuaron J, Dunphy M, Rimner A. Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer. Front Oncol 2013; 2: 208
• 13 Takeuchi S, Khiewvan B, Fox PS. et al. Impact of initial PET/CT staging in terms of clinical stage, management plan, and prognosis in 592 patients with non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2014; 41 (05) 906-914
• 14 National Comprehensive Cancer Network. NCCN Imaging Appropriate Use Criteria (NCCN imaging AUC™). USA: National Comprehensive Cancer Network; 2016
• 15 Vansteenkiste JF, Stroobants SG, De Leyn PR. et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16 (06) 2142-2149 Crossref, Medline, Google Scholar
• 16 Greenspan BS. Role of PET/CT for precision medicine in lung cancer: perspective of the Society of Nuclear Medicine and Molecular Imaging. Transl Lung Cancer Res 2017; 6 (06) 617-620 Crossref, Medline, Google Scholar